Vimarsana
Biggest News Aggregation in the World

Page 35 - Cassava Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cassava Sciences Today - Breaking & Trending Today

Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight - Vimarsana News

Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight

New York, USA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight The Alzheimer's disease market size is

Top 12 Small-Cap Stocks With Highest Upside Potential - Vimarsana News

Top 12 Small-Cap Stocks With Highest Upside Potential

In this piece, we will take a look at the top 12 small-cap stocks with the highest upside potential.

CASSAVA SCIENCES INVESTIGATION UPDATE BY FORMER LOUISIANA - Vimarsana News

CASSAVA SCIENCES INVESTIGATION UPDATE BY FORMER LOUISIANA

NEW ORLEANS, July 07, 2023 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick...

Cassava Sciences (NASDAQ:SAVA) Trading 2.4% Higher - Vimarsana News

Cassava Sciences (NASDAQ:SAVA) Trading 2.4% Higher

Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report)’s share price traded up 2.4% on Thursday . The company traded as high as $22.59 and last traded at $22.56. 856,684 shares were traded during trading, a decline of 13% from the average session volume of 986,435 shares. The stock had previously closed at $22.04. Cassava Sciences Trading […]

Oral Simufilam Slowed Cognitive Decline in a Randomized - Vimarsana News

Oral Simufilam Slowed Cognitive Decline in a Randomized

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild...